Once-Weekly Semaglutide 2 mg vs 1 mg in Patients With Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg Versus 1.0 mg in Patients With Type 2 Diabetes (SUSTAIN FORTE): A Double-Blind, Randomised, Phase 3B Trial
Lancet Diabetes Endocrinol 2021 Jul 19;[EPub Ahead of Print], JP Frías, P Auerbach, HS Bajaj, Y Fukushima, I Lingvay, S Macura, AL Søndergaard, TI Tankova, N Tentolouris, JB BuseFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.